MedTrace Logo

Nirogacestat in Ovarian Granulosa Cell Tumors

NCT05348356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-12-15

No results posted yet for this study

Summary

This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

Conditions

  • Ovarian Granulosa-Stromal Tumor
  • Ovarian Granulosa Cell Tumor
  • Ovarian Cancer

Interventions

DRUG

Nirogacestat

nirogacestat oral tablet

Sponsors & Collaborators

  • SpringWorks Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-30
Primary Completion
2025-07-08
Completion
2025-07-14
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05348356 on ClinicalTrials.gov